Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

Drieklezoor schreef op 3 maart 2023 11:34:

Het (ver-) (wan-) is weer terug, rood zal hij weer zijn of worden, en dat met al die mooie vooruitzichten ?

quote:

Drieklezoor schreef op 3 maart 2023 11:34:

Het (ver-) (wan-) is weer terug, rood zal hij weer zijn of worden, en dat met al die mooie vooruitzichten ?

quote:

Kanshebber schreef op 3 maart 2023 12:13:

De koers wordt door geïnteresseerden in Pharming laag gehouden, zodat ze bij goedkeuring laag kunnen kopen.
Kan soms zo simpel zijn.

quote:

Tube lazervet schreef op 3 maart 2023 12:15:

Stel er komt goedkeuring en het medicijn ligt 2 maanden later in de apotheek (in de VS) wat gaat Pharming doen met al die extra omzet?

quote:

LL schreef op 3 maart 2023 12:35:

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
March 2, 2023 at 7:00 AM EST

NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE), enabling the company to include the United States in the global Phase 2 portion of its ongoing Phase 1/2 study. NTLA-2002 is an in vivo genome editing candidate designed to inactivate the target gene, kallikrein B1 (KLKB1), to permanently reduce plasma kallikrein protein activity and thus prevent HAE attacks after a single-dose treatment.

“The FDA’s acceptance of our IND application to initiate clinical evaluation of NTLA-2002 brings us one step closer to introducing a potentially paradigm-shifting treatment for people living with hereditary angioedema,” said Intellia President and Chief Executive Officer John Leonard, M.D. “The NTLA-2002 IND clearance marks an important milestone for Intellia as we continue our track record of execution as the leader in the genome editing field. We are thrilled to advance the development of NTLA-2002 in the U.S. and are working to rapidly enroll patients in the Phase 2 portion of the study. We look forward to presenting additional data from the first-in-human, Phase 1 portion of the study later this year.”

bron:
ir.intelliatx.com/news-releases/news-...

quote:

Lisa van der Plas schreef op 2 maart 2023 16:20:

[...]

nou ja wat is een GAK ?
dat is gemeentelijke administratie kantoor toch ?

quote:

LL schreef op 3 maart 2023 12:35:

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
March 2, 2023 at 7:00 AM EST

NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE), enabling the company to include the United States in the global Phase 2 portion of its ongoing Phase 1/2 study. NTLA-2002 is an in vivo genome editing candidate designed to inactivate the target gene, kallikrein B1 (KLKB1), to permanently reduce plasma kallikrein protein activity and thus prevent HAE attacks after a single-dose treatment.

“The FDA’s acceptance of our IND application to initiate clinical evaluation of NTLA-2002 brings us one step closer to introducing a potentially paradigm-shifting treatment for people living with hereditary angioedema,” said Intellia President and Chief Executive Officer John Leonard, M.D. “The NTLA-2002 IND clearance marks an important milestone for Intellia as we continue our track record of execution as the leader in the genome editing field. We are thrilled to advance the development of NTLA-2002 in the U.S. and are working to rapidly enroll patients in the Phase 2 portion of the study. We look forward to presenting additional data from the first-in-human, Phase 1 portion of the study later this year.”

bron:
ir.intelliatx.com/news-releases/news-...

quote:

Kanshebber schreef op 3 maart 2023 12:13:

De koers wordt door geïnteresseerden in Pharming laag gehouden, zodat ze bij goedkeuring laag kunnen kopen.
Kan soms zo simpel zijn.

quote:

BassieNL schreef op 3 maart 2023 12:59:

[...]
Je weet hoe het er bij Reata Pharma aan toe ging.

Daar was de FDA beoordelingsdatum 28 februari

- hele maand koersen tussen $40 en $50
- dag vóór de beoordeling: paniek en koers zakt van $45 naar $30 (-33%)
- dag van de beoordeling: koers blijft hangen, beoordeling komt pas nabeurs.
- dag ná de beoordeling: goedkeuring en koers naar $90 (+200%)

quote:

BassieNL schreef op 3 maart 2023 12:59:

[...]
Je weet hoe het er bij Reata Pharma aan toe ging.

Daar was de FDA beoordelingsdatum 28 februari

- hele maand koersen tussen $40 en $50
- dag vóór de beoordeling: paniek en koers zakt van $45 naar $30 (-33%)
- dag van de beoordeling: koers blijft hangen, beoordeling komt pas nabeurs.
- dag ná de beoordeling: goedkeuring en koers naar $90 (+200%)

quote:

Optiebelegger schreef op 3 maart 2023 12:15:

[...]
Als het zo simpel is, moet je nu bijkopen.

quote:

Braniek schreef op 3 maart 2023 12:41:

[...]

heb jij geen vertaalmodus??? wel zo klantvriendelijk